site stats

Griffin nct02874742

WebJan 17, 2024 · The answer to both questions is yes, based in part on updated results from the phase 2 GRIFFIN trial (NCT02874742), says Jacob Laubach, MD, MPP, senior … Web2 days ago · Rebecca Silbermann, MD, MMS, associate professor of medicine at the Division of Hematology/Medical Oncology at Oregon Health & Science University, discusses the relevance of patient-reported outcomes from the phase 2 GRIFFIN study (NCT02874742) and the importance of individualizing treatment for patients with multiple …

ASH 2024 update from the GRIFFIN trial of dara-RVd in newly …

WebDec 7, 2024 · About the GRIFFIN Study 3 The Phase 2 GRIFFIN (NCT02874742) study has enrolled and treated more than 200 adults ages 18-70 years with NDMM and who are eligible for high-dose therapy/autologous ... WebNov 5, 2024 · Introduction: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for relapsed/refractory multiple myeloma and … bolt charged bramble location https://mondo-lirondo.com

DC2 - US English

WebNov 5, 2024 · The phase 2 randomized GRIFFIN study (NCT02874742) evaluates frontline DARA in combination with lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible NDMM. In the primary analysis, ... In GRIFFIN, 93.7% of D-RVd pts and 98.8% of RVd pts reached the minimum institutional CD34 + threshold to perform a … WebSep 15, 2024 · In the phase II GRIFFIN study (NCT02874742), investigators randomized patients with transplant-eligible multiple myeloma 1:1 to receive VRd with or without daratumumab. Patients received 4 ... WebAug 27, 2024 · Zestimate® Home Value: $217,000. 102 Griffin Dr, Greenville, SC is a single family home that contains 1,029 sq ft. It contains 2 bedrooms and 1 bathroom. The Zestimate for this house is $267,600, … gmail view all attachments

GRIFFIN Multiple Myeloma Hub

Category:New DARZALEX® (daratumumab) Data from GRIFFIN …

Tags:Griffin nct02874742

Griffin nct02874742

Abstract - American Society of Hematology

WebJan 12, 2024 · (different to GRIFFIN [NCT02874742], PERSEUS [NCT03710603], CEPHEUS [NCT03652064], or other trials). ATLAS is a key trial suggesting that maintenance approaches with more than one drug, including lenalidomide, should be … WebDec 12, 2024 · RVd followed by high-dose therapy (HDT), autologous stem cell transplant (ASCT), and consolidation is a SoC regimen for US pts with NDMM. This phase 2, randomized study (GRIFFIN; NCT02874742) evaluated DARA plus RVd (D-RVd) in ASCT-eligible NDMM pts. A 16-pt safety run-in showed no safety concerns.

Griffin nct02874742

Did you know?

WebDec 11, 2024 · About the GRIFFIN Study The Phase 2 GRIFFIN (NCT02874742) study evaluated the investigational regimen of DARZALEX ® in combination with VRd and … WebAug 20, 2024 · This trial was registered at www.clinicaltrials.gov as #NCT02874742. Subjects: Clinical Trials and Observations, Lymphoid Neoplasia, Multiple Myeloma. ... The results from GRIFFIN confirm …

WebDaratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study Br J Haematol . 2024 Nov;199(3):355-365. doi: 10.1111/bjh.18432. WebJun 5, 2024 · At a median follow-up of 38.6 months 48.1% of patients in the daratumumab plus RVd arm had a durable MRD negativity status (defined as 10 -5) lasting 6 or more months, compared with 14.6% in the ...

WebNov 23, 2024 · In the primary analysis of the phase 2 GRIFFIN trial (NCT02874742) in autologous stem cell transplant (ASCT)-eligible … WebJan 11, 2024 · The 5-year survival rate for multiple myeloma has risen by nearly 10% over the past decade, and is now at a 56%, largely due to novel agents and their combinations. 21 Over the next decade we will ...

Web2 days ago · Rebecca Silbermann, MD, MMS, associate professor of medicine at the Division of Hematology/Medical Oncology at Oregon Health & Science University, …

WebJun 20, 2024 · “The optimal daratumumab-containing maintenance regimen remains to be determined,” Moreau said. “We looked forward to the results of ongoing trials such as GRIFFIN [NCT02874742], PERSUES [NCT03710603], and AURIGA [NCT03901963] that will provide additional information about the role of daratumumab in the maintenance … gmail view archive mailWebFeb 24, 2024 · During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Jacob Laubach 1 presented an update of the phase II GRIFFIN trial … gmail view all mailWebGRIFFIN (NCT02874742)GRIFFIN (NCT02874742) Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, … bolt charged bramble wowWebAug 27, 2024 · The Phase 2 GRIFFIN (NCT02874742) study evaluated the investigational regimen of DARZALEX ® in combination with RVd and enrolled and treated more than … gmail viewing optionsWebApr 13, 2024 · The phase 2 GRIFFIN study (ClinicalTrials.gov Identifier: NCT02874742) evaluated the addition of the anti-CD38 monoclonal antibody daratumumab to RVd (D-RVd) induction and consolidation with ... gmail view changedWebThe phase II GRIFFIN study (MMY2004, NCT02874742) investigated the use of daratumumab (dara) in combination with bortezomib (V), lenalidomide (R), and dexamethasone (d; dara-VRd) in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for high-dose chemotherapy and autologous stem cell transplant … gmail view full email headerWebFeb 4, 2024 · New data from the phase 2 GRIFFIN trial showed sustained, deep responses in the study population [1]. In the phase 2 GRIFFIN trial (NCT02874742), patients with … gmail view existing filters